These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 33866907)

  • 1. Lasmiditan: an additional therapeutic option for the acute treatment of migraine.
    Martinelli D; Bitetto V; Tassorelli C
    Expert Rev Neurother; 2021 May; 21(5):491-502. PubMed ID: 33866907
    [No Abstract]   [Full Text] [Related]  

  • 2. Lasmiditan for the acute treatment of migraine.
    DeJulio PA; Perese JK; Schuster NM; Oswald JC
    Pain Manag; 2021 Sep; 11(5):437-449. PubMed ID: 33840206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Profiling lasmiditan as a treatment option for migraine.
    Curto M; Cipolla F; Cisale GY; Capi M; Spuntarelli V; Guglielmetti M; Martelletti P; Lionetto L
    Expert Opin Pharmacother; 2020 Feb; 21(2):147-153. PubMed ID: 31766908
    [No Abstract]   [Full Text] [Related]  

  • 4. Lasmiditan for acute treatment of migraine.
    Parikh S
    Drugs Today (Barc); 2021 Feb; 57(2):89-100. PubMed ID: 33656015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials.
    Shapiro RE; Hochstetler HM; Dennehy EB; Khanna R; Doty EG; Berg PH; Starling AJ
    J Headache Pain; 2019 Aug; 20(1):90. PubMed ID: 31464581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The safety and efficacy of the 5-HT 1F receptor agonist lasmiditan in the acute treatment of migraine.
    Raffaelli B; Israel H; Neeb L; Reuter U
    Expert Opin Pharmacother; 2017 Sep; 18(13):1409-1415. PubMed ID: 28749698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of 2-Hour Post-Dose Efficacy of Lasmiditan for the Acute Treatment of Difficult-to-Treat Migraine Attacks.
    Tepper SJ; Vasudeva R; Krege JH; Rathmann SS; Doty E; Vargas BB; Magis D; Komori M
    Headache; 2020 Sep; 60(8):1601-1615. PubMed ID: 32634275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Onset of Efficacy Following Oral Treatment With Lasmiditan for the Acute Treatment of Migraine: Integrated Results From 2 Randomized Double-Blind Placebo-Controlled Phase 3 Clinical Studies.
    Ashina M; Vasudeva R; Jin L; Lombard L; Gray E; Doty EG; Yunes-Medina L; Kinchen KS; Tassorelli C
    Headache; 2019 Nov; 59(10):1788-1801. PubMed ID: 31529622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained responses to lasmiditan: Results from post-hoc analyses of two Phase 3 randomized clinical trials for acute treatment of migraine.
    Doty EG; Krege JH; Jin L; Raskin J; Halker Singh RB; Kalidas K
    Cephalalgia; 2019 Oct; 39(12):1569-1576. PubMed ID: 31266353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Effect and Safety of 5-HT
    Gu P; Chen C; Wu Q; Dong C; Wang T; Wan Q; Dong X
    Biomed Res Int; 2021; 2021():6663591. PubMed ID: 34660796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trajectory of migraine-related disability following long-term treatment with lasmiditan: results of the GLADIATOR study.
    Lipton RB; Lombard L; Ruff DD; Krege JH; Loo LS; Buchanan A; Melby TE; Buse DC
    J Headache Pain; 2020 Feb; 21(1):20. PubMed ID: 32093628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lasmiditan for the acute treatment of migraine: Subgroup analyses by prior response to triptans.
    Knievel K; Buchanan AS; Lombard L; Baygani S; Raskin J; Krege JH; Loo LS; Komori M; Tobin J
    Cephalalgia; 2020 Jan; 40(1):19-27. PubMed ID: 31744319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term efficacy and safety of lasmiditan, a novel 5-HT
    Hou M; Xing H; Li C; Wang X; Deng D; Li J; Zhang P; Chen J
    J Headache Pain; 2020 Jun; 21(1):66. PubMed ID: 32503415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rational Use of Lasmiditan for Acute Migraine Treatment in Adults: A Narrative Review.
    Ferrari A; Rustichelli C
    Clin Ther; 2021 Apr; 43(4):654-670. PubMed ID: 33608115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety Findings in Lasmiditan as a Novel Acute Treatment of Migraine in Chinese Patients: A Post Hoc Analysis of the Randomized Controlled Phase 3 CENTURION Trial.
    Zhou J; Luo G; Xu Y; Yang X; Pan X; Dong Z; Zhong S; Liu H; Ji F; Yu S
    Adv Ther; 2022 Nov; 39(11):5229-5243. PubMed ID: 36114949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lasmiditan for the treatment of migraine.
    Capi M; de Andrés F; Lionetto L; Gentile G; Cipolla F; Negro A; Borro M; Martelletti P; Curto M
    Expert Opin Investig Drugs; 2017 Feb; 26(2):227-234. PubMed ID: 28076702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lasmiditan for the Treatment of Migraines With or Without Aura in Adults.
    Berger AA; Winnick A; Popovsky D; Kaneb A; Berardino K; Kaye AM; Cornett EM; Kaye AD; Viswanath O; Urits I
    Psychopharmacol Bull; 2020 Oct; 50(4 Suppl 1):163-188. PubMed ID: 33633424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lasmiditan mechanism of action - review of a selective 5-HT
    Clemow DB; Johnson KW; Hochstetler HM; Ossipov MH; Hake AM; Blumenfeld AM
    J Headache Pain; 2020 Jun; 21(1):71. PubMed ID: 32522164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lasmiditan efficacy in the acute treatment of migraine was independent of prior response to triptans: Findings from the CENTURION study.
    Reuter U; Krege JH; Lombard L; Gomez Valderas E; Krikke-Workel J; Dell-Agnello G; Dowsett SA; Buse DC
    Cephalalgia; 2022 Jan; 42(1):20-30. PubMed ID: 34644189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lasmiditan Is a New Option for Acute Migraine Treatment.
    Blakely KK; Stallworth K
    Nurs Womens Health; 2020 Aug; 24(4):294-299. PubMed ID: 32663443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.